Paeds · gastroenterology-hepatology-and-nutrition
Non-alcoholic fatty liver disease in children
Also known as Paediatric NAFLD · Metabolic dysfunction-associated steatotic liver disease in children · Paediatric MASLD · Paediatric MASH · Fatty liver disease in children
Fellowship guide to paediatric fatty liver disease, now named metabolic dysfunction-associated steatotic liver disease (MASLD): the multisociety 2023 nomenclature and the steatosis-plus-cardiometabolic-criteria definition, the insulin-resistance and PNPLA3-driven pathophysiology, the distinctive paediatric zone-1 histology, the NASPGHAN 2017 screening strategy with the sex-specific alanine aminotransferase upper limits of 22 units per litre for girls and 26 for boys from age nine to eleven, family-based lifestyle therapy as the cornerstone, the limited role of vitamin E shown in the TONIC trial, and the cardiovascular morbidity that dominates long-term outcome.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Alanine aminotransferase persistently above twice the upper limit of normal for more than three months in an overweight or obese child
- Alanine aminotransferase above 80 units per litre, which signals a higher likelihood of significant liver disease
- Hepatomegaly or splenomegaly on examination of a child with obesity
- Signs of advanced liver disease: jaundice, easy bruising, spider naevi, ascites
- Known MASLD with falling platelets or rising bilirubin suggesting portal hypertension
- Severe obesity in early adolescence with a family history of cirrhosis or hepatocellular carcinoma
Life stages
Care settings
Clinical exam formats
Board mappings
- Recognises paediatric fatty liver disease as the hepatic manifestation of obesity and insulin resistance
- Applies the NASPGHAN screening strategy with sex-specific alanine aminotransferase thresholds
- Explains the 2023 MASLD nomenclature and the steatosis plus cardiometabolic criteria definition
- Constructs a family-based lifestyle management plan and understands the limited role of pharmacotherapy
- Investigation of the overweight child with persistently abnormal liver enzymes
- Distinction of MASLD from other causes of paediatric chronic hepatitis
- Counsels a family on a lifestyle-based management plan for paediatric fatty liver disease
- Coordinates comorbidity screening and longitudinal surveillance
- Stage 1: Recognition of obesity-related fatty liver disease and screening alanine aminotransferase
- Level 2: Stepwise lifestyle management and comorbidity control with multidisciplinary input
- Definition and nomenclature of metabolic dysfunction-associated steatotic liver disease
- Screening thresholds, histological subtypes, and first-line management
- Gastroenterology: the obese child with abnormal liver function tests
- Communication of a chronic lifestyle-responsive diagnosis to a family
- NASPGHAN approach to diagnosis and management of paediatric NAFLD or MASLD
- Screening, comorbidity evaluation, and lifestyle-first therapy
- Recognition and timely referral of the child with fatty liver disease
- Shared decision-making around weight-management and metabolic risk reduction
- Approach to the overweight or obese child with elevated liver enzymes
- Longitudinal cardiometabolic risk surveillance
Overview & Definition
An overweight ten-year-old found on routine screening to have a mildly raised alanine aminotransferase is the everyday face of paediatric fatty liver disease, now the commonest chronic liver condition of childhood in the developed world. The condition is defined by excess triglyceride accumulation within hepatocytes, termed hepatic steatosis, in the setting of overweight or obesity and insulin resistance, and it exists on a spectrum from simple steatosis through steatohepatitis to fibrosis and, rarely, cirrhosis. [1]
A 2023 multisociety Delphi consensus renamed the disorder to reflect this metabolic basis. Non-alcoholic fatty liver disease became metabolic dysfunction-associated steatotic liver disease, and non-alcoholic steatohepatitis became metabolic dysfunction-associated steatohepatitis. The diagnosis now requires hepatic steatosis together with at least one of overweight or obesity, prediabetes or type 2 diabetes, hypertension, hypertriglyceridaemia, or low high-density lipoprotein cholesterol, in the absence of significant alcohol consumption. The new name is more than cosmetic, because it ties the liver disease to the cardiometabolic risk it travels with and aligns paediatric and adult practice. [4]
What makes the paediatric disease distinct is its behaviour over a lifetime. A child diagnosed today carries the condition for decades, and although cirrhosis in childhood is uncommon, the cardiovascular and metabolic consequences are what shape long-term outcome. This is why management is built not around a liver tablet but around sustained family-based change in nutrition, activity, and weight, and why the hepatology assessment is inseparable from a full cardiovascular and metabolic risk evaluation. [1]
References11ShowHide
- [1]Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr, 2017.PMID 28107283
- [2]Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C Prevalence of fatty liver in children and adolescents. Pediatrics, 2006.PMID 17015527
- [3]Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA, 2011.PMID 21521847
- [4]Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol, 2023.PMID 37364790
- [5]Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology, 2024.PMID 38445559
- [6]Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al Guidelines on the management of abnormal liver blood tests. Gut, 2018.PMID 29122851
- [7]Eslam M, Fan JG, Yu ML, Wong VW, Cua IH, Liu CJ, et al The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int, 2025.PMID 40016576
- [8]Sood V, Alam S, Nagral A, Srivastava A, Deshmukh A, Bavdekar A, et al Practice Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease by the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition (ISPGHAN). Indian Pediatr, 2024.PMID 39297398
- [9]Nobili V, Donati B, Panera N, Vongsakulyanon A, Alisi A, Dallapiccola B, et al A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr, 2014.PMID 24345846
- [10]Li M, Shu W, Zou Y, Xiao H, Asihaer Y, Guan M, et al Reversing Metabolic Dysfunction-Associated Steatotic Liver Disease Promotes Healthy Pediatric Cardiovascular Structures: The PROC Study. Am J Gastroenterol, 2024.PMID 38775939
- [11]Carter-Kent C, Brunt EM, Yerian LM, Alkhouri N, Angulo P, Kohli R, et al Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr, 2011.PMID 21240012